Neuphoria Therapeutics
NEUP
9 hedge funds and large institutions have $1.22M invested in Neuphoria Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 9 → 9 (0)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
41% less capital invested
Capital invested by funds: $2.06M → $1.22M (-$839K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LAM
Lewis Asset Management
Lafayette,
California
|
+$16.5K |
| 2 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$11K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$10.6K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$883 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$209K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$17.8K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.5K |
| 4 |
Two Sigma Investments
New York
|
-$15.6K |
| 5 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$10.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
1
Lynx1 Capital Management
San Juan,
Puerto Rico
| $839K | -$10.8K | -820 | -1% |
|
|
2
Point72 Asset Management
Stamford,
Connecticut
| $325K | -$16.5K | -1,250 | -5% |
|
|
3
Two Sigma Investments
New York
| $17.6K | -$15.6K | -1,183 | -45% |
|
|
LAM
4
Lewis Asset Management
Lafayette,
California
| $15.4K | +$16.5K | +1,250 | New |
|
|
BPA
5
Beacon Pointe Advisors
Newport Beach,
California
| $10.3K | +$11K | +833 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $10.2K | +$10.6K | +801 | +2,967% |
|
|
7
RhumbLine Advisers
Boston,
Massachusetts
| $1.34K | +$883 | +67 | +160% |
|
|
APC
8
Aspire Private Capital
Cornelius,
North Carolina
| $206 | – | – | – |
|
|
9
Morgan Stanley
New York
| $97 | -$209K | -15,820 | -100% |
|
10
JP Morgan Chase
New York
| $1 | – | – | – |
|
|
XT
11
XTX Topco
George Town,
Cayman Islands
| – | -$17.8K | -986 | Closed |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| – | -$2.38K | -134 | Closed |
|
NEUP Hedge Fund Activity: Q1 2024 in Review
9 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q1 2024, worth a combined $1.22M — down 41% from $2.06M a quarter earlier.
Fund positioning in NEUP was balanced in Q1 2024: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was Lewis Asset Management, opening a new position worth an estimated $16.5K. The largest seller was Morgan Stanley, cutting an estimated $209K.
- 9 institutional investors held Neuphoria Therapeutics (NEUP) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $1.22M of Neuphoria Therapeutics stock for Q1 2024, down 41% quarter-over-quarter.
- 2 funds opened new Neuphoria Therapeutics positions in Q1 2024 and 2 closed out, a net change of 0 holders.
- The largest Neuphoria Therapeutics buyer in Q1 2024 was Lewis Asset Management, an estimated $16.5K added.
- The largest Neuphoria Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $209K sold.
Based on aggregated 13F filings for Q1 2024.